This listing of claims will replace all prior versions and listings of claims in the application:

## **Listing of Claims:**

- 1. (Previously presented) An anti-IFNAR2 antibody selected from the group consisting of antibody 1F3 produced by a hybridoma with ATCC Accession No. HB 12426 or progeny thereof, antibody 3B7 produced by a hybridoma with ATCC Accession No. HB 12427 or progeny thereof, and antibody 1D3 produced by the hybridoma with ATCC Accession No. HB 12428 or progeny thereof.
- 2. (Original) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with the antibody of claim 1.
- 3. (Original) A polypeptide comprising a portion of the antibody of claim 1 or 2, wherein said portion comprises an antigen binding or a variable region of said antibody.
- 4. (Canceled) The polypeptide of claim 3, wherein said portion comprises at least one complementary determining region of said antibody.
- 5. (Original) The antibody of claim 2, wherein said antibody does not substantially block binding of a Type I interferon to IFNAR2.
  - 6. (Original) The antibody of claim 5, wherein said Type I interferon is IFN $\alpha$ -2/1.
- 7. (Original) The antibody of claim 5, wherein said antibody blocks anti-viral activity of a first Type I interferon and does not block anti-viral activity of a second Type I interferon.
- 8 (Previously presented) The antibody of claim 5, wherein said antibody competes for binding to IFNAR2 with antibody 1D3 produced by a hybridoma with ATCC Accession No. HB 12428 or progeny thereof.

3

- 9. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a monoclonal antibody.
- 10. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a humanized antibody.
- 11. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a human antibody.

## 12-13. (Canceled)

- 14. (Previously presented) A composition comprising the antibody of claims 1-3 or 9-11 and an excipient.
- 15. (New) An anti-IFNAR2 antibody IF3 produced by a hybridoma with ATCC Accession No. HB 12426 or progeny thereof.
- 16. (New) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody IF3 produced by hybridoma with ATCC Accession No. HB 12426 or progeny thereof.
- 17. (New) An anti-IFNAR2 antibody 3B7 produced by a hybridoma with Accession No. HB 12427 or progeny thereof.
- 18. (New) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody 3B7 produced by hybridoma with ATCC Accession No. HB 12427 or progeny thereof.
- 19. (New) An anti-IFNAR2 antibody ID3 produced by a hybridoma with ATCC Accession No. HB 12428 or progeny thereof.

Appl. No. 10/053,302 Amendment dated November 22, 2004 Reply to Final Office Action of September 22, 2004

20. (New) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody ID3 produced by hybridoma with ATCC Accession No. HB 12428 or progeny thereof.